{"entity":{"id":"nct07361510","kind":"trial","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","aka":["ROSETTA Lung-202"],"tldr":"A phase 3 trial of PM8002, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.","summary":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) is a phase 3 interventional study registered as NCT07361510 by Bristol-Myers Squibb, with 750 participants planned, started 2026-03-12 and due to reach its primary completion in 2031-10-14. Interventions recorded: Pumitamig, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07361510","url":"https://clinicaltrials.gov/study/NCT07361510"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","pdl1-high-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pm8002","pembrolizumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07361510","phase":"3","setting":"ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT07361510","source":"https://clinicaltrials.gov/study/NCT07361510","fetchedAt":"2026-10-07T16:55:42.201Z","studySha256":"7268c41fc64f6b217987d48e94772812815b49c61f2890f33054997af24aeb4a","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-30","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":750,"enrolmentType":"ESTIMATED","siteCount":284,"recruitingSiteCount":169,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Finland","France","Germany","Hungary","India","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Peru","Poland","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2026-03-12","startedType":"actual","enrolled":750,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07361510/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}